Cancer Information

VIDEOS

Lung Cancer Video Library - Overall Management for Stage IIIA Disease

Dr. Mark Socinski, University of Pittsburgh Medical Center, describes the primary treatment options for stage IIIA NSCLC, including chemoradiation and surgery, and discusses trial evidence for each approach.

Managing Three Compartments in Stage III Disease (Local, Distant, CNS)

Dr. Mark Socinski, University of Pittsburgh Medical Center, defines the three compartments in stage III (locally advanced) NSCLC, each of which must be treated.

Heterogeneity of Stage III NSCLC/Defining Resectability for Locally Advanced NSCLC

Dr. Mark Socinski, University of Pittsburgh Medical Center, describes the different types of stage III (locally advanced) NSCLC, and states which of these types tend to be resectable.

What is V20 and Why Do Radiation Dose & Field Size Matter?

Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, defines the V20 standard for lung radiation and outlines the advantages of limiting dose and field size in lung radiation therapy.

High vs. Standard Dose Chest Radiation in Stage III Lung Cancer

Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, provides trial evidence showing that patients may not benefit from high dose chest radiation therapy vs. standard dose therapy.

ARTICLES

Thresholds of Deviation (from the Standard of Care)
From the Grace Archives | Originally Published April 9, 2010 | By Dr West | 2 Comments We talk a lot here about the strength of the evidence and the...
Thresholds of Deviation (from the Standard of Care)
From the Grace Archives | Originally Published April 9, 2010 | By Dr West | 2 Comments We talk a lot here about the strength of the evidence and the...
Thresholds of Deviation (from the Standard of Care)
From the Grace Archives | Originally Published April 9, 2010 | By Dr West | 2 Comments We talk a lot here about the strength of the evidence and the...
Thresholds of Deviation (from the Standard of Care)
From the Grace Archives | Originally Published April 9, 2010 | By Dr West | 2 Comments We talk a lot here about the strength of the evidence and the...
Cancer 101 FAQ: Primer on PET Scans
From the Grace Archives | Originally Published September 14, 2010 | By Moderators | Leave a comment The following content is offered by the moderators...

ONLINE COMMUNITY

OncTalk 2020 Live Online Dec. 5
Join the Global Resource for Advancing Cancer Education for 3 LiveOnline panel discussions covering updates on Immunotherapy and Combination...
OncTalk 2020 Live Online Dec. 5
Join the Global Resource for Advancing Cancer Education for 3 LiveOnline panel discussions covering updates on Immunotherapy and Combination...
OncTalk 2020 Live Online Dec. 5
Join the Global Resource for Advancing Cancer Education for 3 LiveOnline panel discussions covering updates on Immunotherapy and Combination...
OncTalk 2020 Live Online Dec. 5
Join the Global Resource for Advancing Cancer Education for 3 LiveOnline panel discussions covering updates on Immunotherapy and Combination...
Pancoast Tumor?
Hi all, I have been reading posts on the forum and I apologise for my questions however I am very concerned. I am a 26 year old female smoker for a...

Recent Comments

Multiple EGFR mutation lung cancer
Yes and yes. 

 

T790M is…
Comment By JanineT GRACE … on Aug 13, 2025 9:22 am
Multiple EGFR mutation lung cancer
T790M and insertion
Comment By JanineT GRACE … on Aug 13, 2025 9:22 am
Worried about lung cancer
Thank you so much for the…
Comment By Worried472 on Sep 26, 2023 12:44 pm
Worried about lung cancer
Hi, I'm sorry you're having…
Comment By Worried472 on Sep 26, 2023 12:44 pm

Immunotherapy Opdivo (Nivolumab) Non-Squamous NSCLC Trial Stopped, Reported as Positive

Article

In January, 2015, the CheckMate 017 trial of the immune checkpoint inhibitor Opdivo (nivolumab) versus the standard chemo agent Taxotere (docetaxel) as second line therapy for patients with advanced squamous NSCLC was reported in a press release to be positive for a significant improvement in overall survival.

Immunotherapy Opdivo (Nivolumab) Approved for Chemo-Pretreated Advanced Squamous NSCLC

Article

It was a big day for the lung cancer world. After seeing the tantalizing promise of immunotherapy for lung cancer over the past 3 years, but outside of the range of routine clinical practice, the anti-PD1 antibody,  immune checkpoint inhibitor Opdivo (nivolumab) was approved by the FDA today for previously treated patients with advanced squamous NSCLC. This was just days after it was formally available for consideration and was based on the clear benefit demonstrated in the pivotal CHECKMATE 017 trial.

Subscribe to Just Diagnosed